Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Peter J. Arduini, a director of Bristol-Myers Squibb, acquired deferred share units convertible to common stock on March 31, 2025.

Summary

• On March 31, 2025, Peter J. Arduini, a director at Bristol-Myers Squibb, acquired 553.369 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Arduini ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $60.99.
• Following the transaction, Arduini beneficially owns 61,491.287 shares of common stock, including deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a neutral to slightly positive sentiment as it aligns director interests with the company's long-term performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing reflects routine director compensation practices within publicly traded companies, where deferred share units are used as a form of equity-based compensation to align director interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include deferred share units, aligning director interests with long-term shareholder value, similar to practices at companies like Pfizer (PFE) and Merck (MRK).
• The vesting and settlement terms, contingent on continued service or a specified future date, are standard in the pharmaceutical industry, mirroring arrangements seen at Johnson & Johnson (JNJ) and AbbVie (ABBV).
• The reporting requirements under Section 16(a) of the Securities Exchange Act are consistently followed by directors across the industry, ensuring transparency in their transactions.

Stakeholder Impact

• The acquisition of deferred share units by a director aligns their interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.
• This transaction has minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Director, Deferred Share Units, Beneficial Ownership, Bristol-Myers Squibb, BMY, Arduini